209 related articles for article (PubMed ID: 9715416)
1. Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians.
Guptan RC; Thakur V; Malhotra V; Sarin SK
J Gastroenterol Hepatol; 1998 Jul; 13(7):675-9. PubMed ID: 9715416
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
Guptan RC; Thakur V; Kazim SN; Sarin SK
J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
[TBL] [Abstract][Full Text] [Related]
5. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
7. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses.
Guptan RC; Thakur V; Raina V; Sarin SK
J Gastroenterol Hepatol; 1999 Sep; 14(9):893-8. PubMed ID: 10535471
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
[TBL] [Abstract][Full Text] [Related]
9. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
10. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
[TBL] [Abstract][Full Text] [Related]
11. Frequency and clinical profile of precore and surface hepatitis B mutants in Asian-Indian patients with chronic liver disease.
Guptan RC; Thakur V; Sarin SK; Banerjee K; Khandekar P
Am J Gastroenterol; 1996 Jul; 91(7):1312-7. PubMed ID: 8677985
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the serum alanine aminotransferase level at the end of interferon treatment and histologic changes in wild-type and precore mutant hepatitis B virus infections.
Bayraktar Y; Koseoglu T; Temizer A; Kayhan B; Van Thiel DH; Uzunalimoglu B
J Viral Hepat; 1996 May; 3(3):137-42. PubMed ID: 8871872
[TBL] [Abstract][Full Text] [Related]
13. Genomic variations in precore and cytotoxic T lymphocyte regions in chronic hepatitis B in relationship to interferon responsiveness.
Shindo M; Okuno T
Liver; 2000 Apr; 20(2):136-42. PubMed ID: 10847482
[TBL] [Abstract][Full Text] [Related]
14. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.
Habersetzer F; Zoulim F; Jusot JF; Zhang X; Trabaud MA; Chevallier P; Chevallier M; Ahmed SN; Sepetjan M; Comanor L; Minor J; Trépo C
J Viral Hepat; 1998 Nov; 5(6):407-14. PubMed ID: 9857350
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay.
Gerken G; Gomes J; Lampertico P; Colombo M; Rothaar T; Trippler M; Colucci G
J Virol Methods; 1998 Oct; 74(2):155-65. PubMed ID: 9779615
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B.
Shindo M; Hamada K; Koya S; Sokawa Y; Okuno T
Am J Gastroenterol; 1999 Aug; 94(8):2237-45. PubMed ID: 10445556
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic vaccination in chronic hepatitis B.
Senturk H; Tabak F; Akdogan M; Erdem L; Mert A; Ozaras R; Sander E; Ozbay G; Badur S
J Gastroenterol Hepatol; 2002 Jan; 17(1):72-6. PubMed ID: 11895556
[TBL] [Abstract][Full Text] [Related]
19. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
Akhan SC; Yulugkural Z; Vahaboglu H
Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
[TBL] [Abstract][Full Text] [Related]
20. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
